[Federal Register Volume 69, Number 81 (Tuesday, April 27, 2004)]
[Notices]
[Pages 22806-22810]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-9494]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Development of Influenza Surveillance Networks

    Announcement Type: New.
    Funding Opportunity Number: 04106.
    Catalog of Federal Domestic Assistance Number: 93.283.
    Key Dates:
    Letter of Intent Deadline: May 27, 2004.
    Application Deadline: June 28, 2004.
    Executive Summary: An influenza pandemic has greater potential than 
any other naturally occurring infectious disease event to cause large 
and rapid global and domestic increases in deaths and serious 
illnesses. Preparedness is the key to substantially reducing the 
health, social, and economic impacts of an influenza pandemic and other 
public health emergencies. One component of preparedness involves 
understanding the impact that annual epidemics of influenza has on the 
population. These data regarding impact are critical to the development 
of prevention and control measures such as vaccination policies. 
Vaccination efforts are the cornerstone of influenza prevention and 
will be the primary means of mitigating the impact of an influenza 
pandemic.
    The systematic collection of influenza surveillance data over time 
is necessary to monitor and track influenza virus and disease activity 
and is essential to understanding the impact influenza has on a 
country's population. Improving surveillance systems by developing 
influenza surveillance networks is critical for the rapid detection of 
new variants, including those with pandemic potential, to contribute to 
the global surveillance system. Global collaboration, under the 
coordination of the World Health Organization (WHO), is a key feature 
of influenza surveillance. WHO established an international laboratory-
based surveillance network for influenza in 1948. The network currently 
consists of 112 National Influenza Center (NIC) laboratories in 83 
countries, and four WHO Collaborating Centers for Reference and 
Research of Influenza (including one located at the Centers for Disease 
Control and Prevention). The primary purposes of the WHO network are to 
detect the emergence and spread of new antigenic variants of influenza, 
to use this information to update the formulation of influenza vaccine, 
and to provide as much warning as possible about the next pandemic. 
This system provides the foundation of worldwide influenza prevention 
and control.
    Monitoring of influenza viruses and providing contributions to the 
global surveillance system, will assure that data used in annual WHO 
vaccine recommendations are relevant to each country that participates. 
Increased participation in the global surveillance system for influenza 
viruses will enhance each country's ability to monitor severe 
respiratory illness, to develop vaccine policy and to help build global 
and regional strategies for the prevention and control of influenza. 
Monitoring influenza disease activity is important to facilitate 
resource planning, communication, intervention, and investigation.
    This announcement seeks to support foreign governments through 
their Ministries of Health or other responsible Ministries for human 
health in the development or improvement of epidemiologic and virologic 
influenza surveillance networks. These networks will focus on the 
systematic collection of virological and epidemiological information 
for influenza. This support is meant to enhance, and not to supplant, 
current influenza surveillance activities and proposals should build 
upon infrastructure already in place. Preference will be given to 
countries where resources are currently limited and influenza 
surveillance is not well established due to lack of resources.

I. Funding Opportunity Description

    Authority:  This program is authorized under sections 301(a) and 
307 of the Public Health Service Act, [42 U.S.C. sections 241(a), 
and 2421], as amended.

    Purpose: The purpose of the program is to provide support and 
assistance to foreign governments for the development or improvement of 
influenza surveillance networks. These networks will focus on the 
systematic collection of virological and epidemiological information 
for influenza. Countries applying for support must have an active WHO 
National Influenza Center recognized by WHO. This program addresses the 
``Healthy People 2010'' focus area of Immunization and Infectious 
diseases.
    Measurable outcomes of the program will be in alignment with the 
following performance goal for the National Center for Infectious 
Diseases: Protect Americans from infectious diseases.
    The objectives of this program are to (1) Establish or enhance an 
active influenza surveillance network that uses standardized data 
collection instruments, operational definitions, and laboratory 
diagnostic tests to enhance surveillance for influenza at three or more 
sites within the country; (2) use the experience gained to expand the 
surveillance system to include additional sites; (3) improve local 
laboratory diagnostic capabilities by supporting and enhancing those 
local laboratories that participate in influenza surveillance; (4) 
develop educational and training opportunities for local public health 
practitioners as part of broader efforts to improve public health 
infrastructure in the region; and (5) improve communications and data 
exchange between laboratories and epidemiologists in the global 
influenza surveillance network by expanding the network and improving 
the reporting of data from surveillance sites, laboratories, and 
National Influenza Centers.
    Activities: Awardee activities for this program are as follows:
     Develop a nationwide system to collect virologic 
and epidemiologic data for influenza by establishing 5 or more sites 
with good geographic distribution throughout the country. Each site 
will consist of a local laboratory and one or more clinics or hospitals 
for data collection. Each site should:
    [ctrcir] Conduct virologic and epidemiologic surveillance for 
influenza by collecting information year round in countries or regions 
of countries with tropical and subtropical climates; and/or by 
collecting surveillance information during the period of respiratory 
illness circulation in countries or regions of countries with temperate 
climates.
    [ctrcir] Have laboratory capacity for performing influenza virus 
isolation and typing.

[[Page 22807]]

    [ctrcir] Collect information on influenza like illnesses and/or 
severe respiratory disease at each site by building on information that 
is already available. Possible sources of information are (1) recording 
influenza-like-illness visits to physicians or primary care clinics or 
hospitals based on a standard case definition. (2) Monitoring hospital 
admissions for severe respiratory illness and pneumonia based on a case 
definition. Patient information such as age, patient history and other 
relevant information should be collected.
    [ctrcir] Collect a subset of at least 10 (and preferably up to 25) 
specimens from the patient populations under surveillance with febrile, 
acute upper respiratory illness. These specimens should be collected 
weekly during the period of surveillance (based on climate) using a 
standard case definition (preferably WHO) and should be submitted to 
the local laboratory for the site.
    [ctrcir] During unusual outbreaks of influenza, such as outbreaks 
with unusual epidemiologic characteristics, or those related to 
infections by avian or other animal influenza viruses, collect 
epidemiologic information to characterize the outbreak and collect 
additional samples for viral isolation and submittal to the site 
laboratory. Report the outbreak to the National Influenza Center.
    [ctrcir] Prepare and provide regular weekly reports on the 
epidemiologic information that has been collected (influenza-like-
illness and/or severe respiratory illness) to the local laboratory and 
to the National Influenza Center.
    [ctrcir] The laboratory will perform viral isolation for influenza 
viruses either in tissue culture or in eggs. Type positive isolates for 
influenza A and B, and if possible, subtype influenza viruses.
    [ctrcir] Store original clinical materials at -70 until the 
beginning of the next influenza season.
    [ctrcir] Submit viral isolates to the National Influenza Center 
within the country on at least a monthly basis for more complete 
analysis.
     The WHO National Influenza Center (NIC) within a 
country can be one of the surveillance sites and as such conduct all 
the activities listed above. If there are two or more NICs within a 
country each NIC could participate as a site, however NICs within a 
single country should work together and place emphasis on the addition 
of new surveillance sites. In addition, the NIC(s) should act as the 
focal point and authority within their country on influenza 
surveillance and be the main point of communication with WHO and WHO 
Collaborating Centers for the submittal of virus isolates and 
information into the global surveillance system. Each National 
Influenza Center (NIC) also will be responsible for the following 
activities:
    [ctrcir] Performing preliminary antigenic and, if possible genetic, 
characterization on the virus isolates submitted from the laboratories 
in the surveillance sites (including those isolates grown at the NIC).
    [ctrcir] Send representative virus isolates to one of the four WHO 
Collaborating Centers for Influenza, including any low reacting 
viruses, as tested using the WHO reagent kit, each month during the 
period of surveillance and more frequently, if possible.
    [ctrcir] If any viruses are unsubtypable as tested using the WHO 
kit, alert WHO and send the virus isolate to one of the four WHO 
Collaborating Centers for Influenza immediately.
    [ctrcir] During the period of surveillance, provide weekly 
influenza surveillance information to WHO through FluNet.
    [ctrcir] Provide an annual national summary on influenza activity, 
virological information and other relevant information on influenza to 
WHO and the WHO Collaborating Center in Atlanta, GA.
    [ctrcir] Provide technical expertise and training to support the 
surveillance sites and laboratories in the national network.
     Foreign Governments applying for funding through 
this cooperative agreement should play a substantial role in the 
development and support of the influenza surveillance network.
    [ctrcir] Facilitate the sharing of influenza surveillance 
information with the WHO Global Influenza Surveillance network by 
facilitating the regular exchange of information and viruses with one 
of the four WHO Collaborating Centers.
    [ctrcir] Provide continued support for influenza activities within 
the country and develop a plan for increased participation in the 
global influenza surveillance network over a five-year period.
    [ctrcir] Consider developing a task force or working group for 
influenza to determine ways to improve national influenza surveillance, 
develop prevention and control measures such as vaccine policy and work 
on pandemic preparedness.
     Facilitate communication between the veterinary 
and the human side of influenza surveillance. Develop systems for the 
sharing of information.
    In a cooperative agreement, CDC staff is substantially involved in 
the program activities, above and beyond routine grant monitoring.
    CDC Activities for this program are as follows:
     Provide technical assistance on techniques and 
reagents for the identification of influenza viruses. Annually provide 
the WHO reagent kit, which is produced and distributed by the WHO 
Collaborating Center for Influenza in Atlanta, GA.
     Provide epidemiological and laboratory training.
     Provide technical consultation on the 
development of country networks.
     Provide confirmation of antigenic analysis and 
more detailed characterization information on the influenza virus 
isolates submitted to CDC with written reports back to the National 
Influenza Center.
     Provide technical advice on the conduct of 
epidemiologic outbreak investigations.

II. Award Information

    Type of Award: Cooperative Agreement.
    CDC involvement in this program is listed in the Activities Section 
above.
    Fiscal Year Funds: 2004.
    Approximate Total Funding: $1,000,000.
    Approximate Number of Awards: 5-10.
    Approximate Average Award: $ 50,000 to 250,000 (This amount is for 
the first 12-month budget period, and includes both direct and indirect 
costs).
    Floor of Award Range: None.
    Ceiling of Award Range: $250,000.
    Anticipated Award Date: August 1, 2004.
    Budget Period Length: 12 months.
    Project Period Length: 5 years.
    Throughout the project period, CDC's commitment to continuation of 
awards will be conditioned on the availability of funds, evidence of 
satisfactory progress by the recipient (as documented in required 
reports), and the determination that continued funding is in the best 
interest of the Federal Government.

III. Eligibility Information

III.1. Eligible applicants

    Applications may be submitted by foreign governments, Ministries of 
Health, or other government offices responsible for disease 
surveillance in humans. Only one application per country will be 
accepted.

III.2. Cost Sharing or Matching

    Cost sharing or matching is not required for this program. However, 
the support provided through this cooperative agreement is meant to 
enhance, and not supplant, current influenza surveillance activities.

[[Page 22808]]

III.3. Other

    If you request a funding amount greater than the ceiling of the 
award range, your application will be considered non-responsive, and 
will not be entered into the review process. You will be notified that 
your application did not meet the submission requirements.
    If your application is incomplete or non-responsive to the 
requirements listed in this section, it will not be entered into the 
review process. You will be notified that your application did not meet 
submission requirements.
    This program is not designed or intended to support research, 
therefore no research will be supported under this cooperative 
agreement. Any applications proposing research will be considered non-
responsive.
    In order to apply and be eligible for this funding, your Country 
must have at least one National Influenza Center (NIC) of record at 
WHO. Documentation of WHO National Influenza Center status by the 
Ministry of Health and WHO will be sufficient to establish eligibility. 
Participation as a NIC is a requirement because to meet the goal of 
this announcement a significant number of the recipient activities 
require information and work to be conducted, reported and submitted 
through the WHO Surveillance network.


    Note: Title 2 of the United States Code section 1611 states that 
an organization described in section 501(c)(4) of the Internal 
Revenue Code that engages in lobbying activities is not eligible to 
receive Federal funds constituting an award, grant, or loan.

IV. Application and Submission Information

IV.1. Address To Request Application Package

    To apply for this funding opportunity use application form PHS 
5161. Application forms and instructions are available on the CDC Web 
site, at the following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
    If you do not have access to the Internet, or if you have 
difficulty accessing the forms on-line, you may contact the CDC 
Procurement and Grants Office Technical Information Management Section 
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to 
you.

IV.2. Content and Form of Submission

    Letter of Intent (LOI): An LOI is requested. Your LOI must be 
written in the following format:
     Maximum number of pages: 4
     Font size: 12-point unreduced
     Single spaced
     Paper size: 8.5 by 11 inches
     Page margin size: One inch
     Printed only on one side of page
     Written in plain language, avoid jargon
    Your LOI must contain the following information:
     Name of the government entity that is applying
     Documentation of National Influenza Center 
status
     Name and contact information for point of 
contact
    Application: You must submit a project narrative with your 
application forms. The narrative must be submitted in the following 
format:
     Maximum number of pages: 25
    If your narrative exceeds the page limit, only the first pages, 
which are within the page limit, will be reviewed.
     Font size: 12 point unreduced
     single spaced
     Paper size: 8.5 by 11 inches
     Page margin size: One inch
     Printed only on one side of page
     Held together only by rubber bands or metal 
clips; not bound in any other way.
    Your narrative should address activities to be conducted over the 
entire project period, and must include the following items in the 
order listed:
     Plan
     Documentation of Results
     Capacity
     Proposed Program Plan
     Goals
     Objectives
     Operational Plan
     Evaluation Plan
     Collaborations
     Budget and justification (not included in page 
limit) With staffing breakdown and justification, provide a line item 
budget and a narrative with justification for all requested costs, and 
separate line-item budgets for each research area. Be to include, if 
any, in-kind support or other contributions that will be provided by 
your country as part of the total project, but for which you are not 
requesting funding. Budgets should be consistent with the purpose, 
objectives and research activities and include:
     Line-item breakdown and justification for all 
personnel, i.e., name, position title, annual salary, percentage of 
time and effort, and amount requested.
     For each contract: (1) Name of proposed 
contractor; (2) breakdown and justification for estimated costs; (3) 
description and scope of activities to be performed by contractor; (4) 
period of performance; (5) method of contractor selection (e.g., sole-
source of competitive solicitation); and (6) methods of accountability.
    Additional information may be included in the application 
appendices. The appendices will not be counted toward the narrative 
page limit. This additional information includes:
     Curriculum Vitaes
     Resumes
     Organizational Charts
     Letters of Support may be included.
    You are required to have a Dun and Bradstreet Data Universal 
Numbering System (DUNS) number to apply for a grant or cooperative 
agreement from the Federal government. The DUNS number is a nine-digit 
identification number, which uniquely identifies business entities. 
Obtaining a DUNS number is easy and there is no charge. To obtain a 
DUNS number, access http://www.dunandbradstreet.com or call 1-866-705-
5711.
    For more information, see the CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm.
    If your application form does not have a DUNS number field, please 
write your DUNS number at the top of the first page of your 
application, and/or include your DUNS number in your application cover 
letter.
    Additional requirements that may require you to submit additional 
documentation with your application are listed in section ``VI.2. 
Administrative and National Policy Requirements.''

IV.3. Submission Dates and Times

    LOI Deadline Date: May 27, 2004.
    CDC requests that you send a LOI if you intend to apply for this 
program. Although the LOI is not required, not binding, and does not 
enter into the review of your subsequent application, the LOI will be 
used to gauge the level of interest in this program, and to allow CDC 
to plan the application review.
    Application Deadline Date: June 28, 2004.
    Explanation of Deadlines: Applications must be received in the CDC 
Procurement and Grants Office by 4 p.m. eastern time on the deadline 
date. If you send your application by the United States Postal Service 
or commercial delivery service, you must ensure that the carrier will 
be able to guarantee delivery of the application by the closing date 
and time. If CDC receives your application after closing due to: (1) 
carrier error, when the carrier accepted the package with a guarantee 
for delivery by the closing date and time, or (2) significant weather 
delays or natural disasters, you will be given the opportunity to 
submit documentation of the carriers guarantee. If the documentation 
verifies a carrier problem, CDC will consider the

[[Page 22809]]

application as having been received by the deadline.
    This announcement is the definitive guide on application submission 
address and deadline. It supersedes information provided in the 
application instructions. If your application does not meet the 
deadline above, it will not be eligible for review, and will be 
discarded. You will be notified that your application did not meet the 
submission requirements.
    CDC will not notify you upon receipt of your application. If you 
have a question about the receipt of your application, first contact 
your courier. If you still have a question, contact the PGO-TIM staff 
at: 770-488-2700. Before calling, please wait two to three days after 
the application deadline. This will allow time for applications to be 
processed and logged.

IV.4. Intergovernmental Review of Applications

    Executive Order 12372 does not apply to this program.

IV.5. Funding restrictions

    Restrictions, which must be taken into account while writing your 
budget, are as follows:
    Use of Funds
     Funds may be spent for reasonable program 
purposes, including personnel, travel, supplies, and services. 
Equipment may be purchased if deemed necessary to accomplish program 
objectives, however, prior approval by CDC officials must be requested 
in writing.
     The costs that are generally allowable in grants 
to domestic organizations are allowable to foreign institutions and 
international organizations, with the following exception: With the 
exception of the American University, Beirut and the World Health 
Organization, Indirect Costs will not be paid (either directly or 
through sub-award) to organizations located outside the territorial 
limits of the United States or to international organizations 
regardless of their location.
     The applicant may contract with other 
organizations under this program; however the applicant must perform a 
substantial portion of the activities (including program management and 
operations, and delivery of prevention services for which funds are 
required.)
     All requests for funds contained in the budget, 
shall be stated in U.S. dollars. Once an award is made, CDC will not 
compensate foreign grantees for currency exchange fluctuations through 
the issuance of supplemental awards.
     You must obtain annual audit of these CDC funds 
(program-specific audit) by a U.S.--based audit firm with international 
branches and current licensure/authority in-country, and in accordance 
with International Accounting Standards or equivalent standard(s) 
approved in writing by CDC.
     A fiscal Recipient Capability Assessment may be 
required, prior to or post award, in order to review the applicant's 
business management and fiscal capabilities regarding the handling of 
U.S. Federal funds.
     Awards will not allow reimbursement of pre-award 
costs.
    Guidance for completing your budget can be found on the CDC Web 
site, at the following Internet address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm.

IV.6. Other Submission Requirements

    LOI Submission Address: Submit your LOI by express mail, delivery 
service, fax, or E-mail to: Ken Fortune, National Center for Infectious 
Diseases, Center for Disease Control and Prevention, Mailstop C-19, 
1600 Clifton Road, NE., Atlanta, GA 30333, FAX: 404-639-4195, E-mail: 
[email protected].
    Application Submission Address: Submit the original and two hard 
copies of your application by mail or express delivery service to: 
Technical Information Management-PA 04106, CDC Procurement and 
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341.
    Applications may not be submitted electronically at this time.

V. Application Review Information

V.1. Criteria

    You are required to provide measures of effectiveness that will 
demonstrate the accomplishment of the various identified objectives of 
the cooperative agreement. Measures of effectiveness must relate to the 
performance goals stated in the ``Purpose'' section of this 
announcement. Measures must be objective and quantitative, and must 
measure the intended outcome. These measures of effectiveness must be 
submitted with the application and will be an element of evaluation.
    Your application will be evaluated against the following criteria:
     Objectives and Technical Approach (50 points 
total)
     Does the applicant describe specific objectives 
of the proposed program that are consistent with the purpose and goals 
of this announcement and which are measurable and time-phased? (10 
points)
     Does the applicant identify appropriate sites 
with adequate geographic distribution for network? (10 points)
     Does the applicant present a detailed 
operational plan for initiating and conducting the program, which 
clearly and appropriately addresses all recipient activities that are 
feasible? Does the applicant clearly identify specific assigned 
responsibilities for all key professional personnel? Does the plan 
clearly describe the applicant's technical approach/methods for 
developing and conducting the proposed program and evaluation and does 
it appear feasible and adequate to accomplish the objectives? Does the 
applicant describe the existence of or plans to establish partnerships? 
(10 points)
     Does the applicant describe adequate and 
appropriate collaborations with other health agencies during various 
phases of the project? (10 points)
     Has the applicant provided a detailed, adequate 
and feasible plan for evaluating program results? This includes plans 
for evaluating the improvement of the influenza surveillance network as 
well as plans for evaluating other aspects of the collaboration (e.g., 
training). (10 points)
     Capacity (35 points total)
     Does the applicant describe adequate resources 
and facilities (both technical and administrative) for conducting the 
project? This includes the capacity to conduct quality laboratory 
measurements and produce and distribute reports? (20 points)
     Does the applicant provide documentation that 
professional personnel involved in the project are qualified and have 
past experience and achievements in research and programs related to 
the program (as evidenced by curriculum vitae, publications, etc.)? (15 
points)
     Background and Need (10 points)
    Does the applicant adequately discuss the background for the 
proposed project and demonstrate a clear understanding of the purpose 
and objectives of this cooperative agreement program? Does the 
applicant illustrate and justify the need for the proposed project that 
is consistent with the purpose and objectives of this program?
     Measures of Effectiveness (5 points) Does the 
applicant provide Measures of Effectiveness that will demonstrate the 
accomplishment of the various identified objectives of the grant and 
the degree to which the measures are objective/quantitative and 
adequately measure the intended outcome?
     Budget and Justification (not scored): Does the 
applicant propose a budget that is reasonable, clearly

[[Page 22810]]

justifiable, and consistent with the intended use of cooperative 
agreement funds?

V.2. Review and Selection Process

    Applications will be reviewed for completeness by the Procurement 
and Grants Office (PGO) staff, and for responsiveness by the National 
Center for Infectious Diseases. Incomplete applications and 
applications that are non-responsive to the eligibility criteria will 
not advance through the review process. Applicants will be notified 
that their application did not meet submission requirements.
    An objective review panel will evaluate complete and responsive 
applications according to the criteria listed in the ``V.1. Criteria'' 
section above.
    In addition, the following factors may affect the funding decision: 
Funding preference will be given to countries where resources are 
currently limited and influenza surveillance is not well established 
due to lack of resources and where there have been problems with avian 
influenza outbreaks posing threats to human health either in their 
country or surrounding countries. This would include countries in the 
following geographic region: Asia

V.3. Anticipated Announcement and Award Dates

    Anticipated Award Date: August 1, 2004.

VI. Award Administration Information

VI.1. Award Notices

    Successful applicants will receive a Notice of Grant Award (NGA) 
from the CDC Procurement and Grants Office. The NGA shall be the only 
binding, authorizing document between the recipient and CDC. The NGA 
will be signed by an authorized Grants Management Officer, and mailed 
to the recipient fiscal officer identified in the application.
    Unsuccessful applicants will receive notification of the results of 
the application review by mail.

VI.2. Administrative and National Policy Requirements

    45 CFR Part 74 and Part 92 For more information on the Code of 
Federal Regulations, see the National Archives and Records 
Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
    The following additional requirements apply to this project:

     AR-9 Paperwork Reduction Act Requirements
     AR-10 Smoke-Free Workplace Requirements
     AR-11 Healthy People 2010
     AR-12 Lobbying Restrictions
     AR-15 Proof of Non-Profit Status
     AR-25 Release and Sharing of Data
    Additional information on these requirements can be found on the 
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm.

VI.3. Reporting Requirements

    You must provide CDC with an original, plus two hard copies of the 
following reports:
    1. Interim progress report, no less than 90 days before the end of 
the budget period The progress report will serve as your non-competing 
continuation application, and must contain the following elements:
    a. Current Budget Period Activities Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.
    d. Budget.
    e. Additional Requested Information.
    f. Measures of Effectiveness.
    2. Financial status report and annual progress report, no more than 
90 days after the end of the budget period.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    These reports must be mailed to the Grants Management or Contract 
Specialist listed in the ``Agency Contacts'' section of this 
announcement.

VII. Agency Contacts

    For general questions about this announcement, contact: Technical 
Information Management Section, CDC Procurement and Grants Office, 2920 
Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-2700.
    For program technical assistance, contact: Ann Moen, Project 
Officer, National Center for Infectious Diseases, Center for Disease 
Control and Prevention Mailstop G-16, 1600 Clifton Road, NE., Atlanta, 
GA 30333, Telephone: 404-639-4652, E-mail: [email protected].
    For financial, grants management, or budget assistance, contact: 
Steward Nichols, Grants Management Specialist, CDC Procurement and 
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-
488-2788, E-mail: [email protected].

    Dated: April 20, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention.
[FR Doc. 04-9494 Filed 4-26-04; 8:45 am]
BILLING CODE 4163-18-P